Cargando…

GAS5 long non-coding RNA in malignant pleural mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive cancer with short overall survival. Long non-coding RNAs (lncRNA) are a class of RNAs more than 200 nucleotides long that do not code for protein and are part of the 90% of the human genome that is transcribed. Earlier experimental st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Renganathan, Arun, Kresoja-Rakic, Jelena, Echeverry, Nohemy, Ziltener, Gabriela, Vrugt, Bart, Opitz, Isabelle, Stahel, Rolf A, Felley-Bosco, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039656/ https://www.ncbi.nlm.nih.gov/pubmed/24885398 http://dx.doi.org/10.1186/1476-4598-13-119

Ejemplares similares

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
por: Oehl, Kathrin, et al.
Publicado: (2018)

Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis
por: Thies, Svenja, et al.
Publicado: (2015)

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2017)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2016)

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
por: Echeverry, N, et al.
Publicado: (2015)

miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2019)

Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models
por: Barbone, Dario, et al.
Publicado: (2015)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment
por: Hariharan, Ananya, et al.
Publicado: (2022)

CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma
por: Sun, Suna, et al.
Publicado: (2022)

Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring
por: Cerciello, Ferdinando, et al.
Publicado: (2013)

Genomic landscape of pleural and peritoneal mesothelioma tumours
por: Hiltbrunner, Stefanie, et al.
Publicado: (2022)

Non-Coding Transcript Heterogeneity in Mesothelioma: Insights from Asbestos-Exposed Mice
por: Felley-Bosco, Emanuela, et al.
Publicado: (2018)

The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition
por: Felley-Bosco, Emanuela, et al.
Publicado: (2023)

Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line
por: Blum, Walter, et al.
Publicado: (2015)

Hedgehog Signaling in Mesothelioma: 2019 Status
por: Felley-Bosco, Emanuela
Publicado: (2019)

Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions
por: Felley-Bosco, Emanuela
Publicado: (2018)

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
por: Schröder, Christina, et al.
Publicado: (2019)

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
por: Belyanskaya, Larisa L, et al.
Publicado: (2007)

Mesothelioma Driver Genes, Ferroptosis, and Therapy
por: Felley-Bosco, Emanuela, et al.
Publicado: (2019)

Exploring the Expression of the «Dark Matter» of the Genome in Mesothelioma for Potentially Predictive Biomarkers for Prognosis and Immunotherapy
por: Felley-Bosco, Emanuela
Publicado: (2023)

Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma
por: Vrugt, Bart, et al.
Publicado: (2023)

RNA editing in mesothelioma: a look forward
por: Hariharan, Ananya, et al.
Publicado: (2020)

Differential Effects of Lovastatin on Cisplatin Responses in Normal Human Mesothelial Cells versus Cancer Cells: Implication for Therapy
por: Shi, Yandong, et al.
Publicado: (2012)

Hand2 delineates mesothelium progenitors and is reactivated in mesothelioma
por: Prummel, Karin D., et al.
Publicado: (2022)

Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma
por: Meerang, Mayura, et al.
Publicado: (2020)

Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A
por: Abukar, Asra, et al.
Publicado: (2021)

Prospective validation and extension of the Multimodality Prognostic Score for the treatment allocation of pleural mesothelioma patients
por: Greb, Daria, et al.
Publicado: (2022)

Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin
por: Shi, Yandong, et al.
Publicado: (2012)

Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2021)

Proposal for a new local recurrence score in patients with recurrent malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2022)

Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells
por: Blum, Walter, et al.
Publicado: (2017)

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
por: Petrausch, Ulf, et al.
Publicado: (2012)

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
por: Schuberth, Petra C, et al.
Publicado: (2013)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Quality of Life Is Not Deteriorated After Extrapleural Pneumonectomy vs. (Extended) Pleurectomy/Decortication in Patients With Malignant Pleural Mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2021)

Prognostic Value of EMT Gene Signature in Malignant Mesothelioma
por: Wu, Licun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l75r3mrtlcr424cer0qudfacfn